INTRODUCTION 23
Topical microbicides are a promising method for prevention of sexually 24 transmitted disease (STD) in women who are not able to persuade their partners to use 25 condoms. Interest in the antimicrobial capabilities of spermicides began with products 26 containing Nonoxynol-9 (non-9), a non-ionic detergent that is the active ingredient in 27 many existing spermicides. Non-9 has been shown to inhibit HIV (12), Chlamydia 28 trachomatis (2, 5, 14, 20) , Neisseria gonorrhoeae (23), 24) , and Trichomonas 29 vaginalis (22) both in-vitro and in-vivo. Its potential value as a microbicide is 30 controversial, however, because results of testing have not been consistent and because it 31 is toxic to cells used in in-vitro testing (1, 7, 10, 13, 15) . It can increase susceptibility to 32 HPV in mice (21) and with frequent use, non-9 appears to actually increase a person's 33 chance of contracting HIV because of the epithelial lesions it causes (8, 26) . For these 34 reasons, attention has recently turned from surfactants (like non-9) to other compounds, 35 such as lipids and peptides, as possible topical microbicide candidates (11, 16, 18, 19, 27, 36 28) . 37
The ideal topical microbicide would prevent multiple STDs, but the experiments 38 reported here have focused on C. trachomatis specifically because it is the most 39 6 from E Fougera & CO (a division of Altana Inc., Melville, New York 11747) and stored 92 at room temperature until use. 93
Controls. Penicillin G (Sigma 61K1045) and polymyxin B (Sigma P4932) were 94 used as negative and positive inhibition controls respectively in the MCC assay. An 95 inoculum control, in which no drug was added, was included for each C. trachomatis 96 strain at each time-point to monitor normal inclusion formation. Percent inhibition of 97 inclusion formation was calculated using this inoculum control. A cell control (no drug, 98 no inoculum) was included in order to monitor McCoy cell morphology and possible 99 cross-contamination. SPG and 10% [vol/vol] Minimum Cidal Concentration (MCC) Assay adapted for Non-9. We slightly 126 modified our previously published pre-inoculation assay (16) to adjust for the 127 cytotoxicity of non-9 as follows. McCoy cell 96-well plates were set up as described in 128 the previous section. On the day of the assay, ten four-fold dilutions of non-9 (starting at 129 a concentration of 2% [vol/vol] ), polymyxin B (starting at a concentration of 1.44mM), 130 and penicillin G (starting at a concentration of 5.37mM) were made in SPG. C. 131 trachomatis inoculum was added to the samples in the same manner as before except at a 132 higher concentration (1 X 10 7 IFU). After incubation at room temperature for 120 133 minutes, the reaction mixture was diluted 1:1600 in SPG to effectively eliminate the non-134 9. The remainder of the assay was performed as described previously except that 0. 
RESULTS

147
Cytotoxicity of microbicides to McCoy cells as determined with the 148
AlamarBlue
TM assay. In our standard MCC assay, all compounds were exposed to EBs 149 and then compound-organism mixtures were diluted 1:40 in SPG before addition to 150
McCoy cells, resulting in exposure of cells to maximum concentrations of 0.625%, 151 2.5µM, and 0.625mM for surgilube, the peptides, and 1-OG respectively. In our toxicity-152 adapted MCC assay, EBs were exposed to maximum non-9 concentrations of 1% and 153 non-9-organism mixtures were diluted 1:1600 before addition to McCoy cells, resulting 154 in exposure of the cells to a maximum non-9 concentration of 0.000625%. We tested 155 whether any residual microbicide in the dilution was toxic to McCoy cells used to culture 156 viable organisms in this assay system. None of the concentrations of the microbicides 157 were toxic to McCoy cells in our assay conditions. Any reduction of C. trachomatis 158 D and E. We tested non-9 against serovars D, E, F, J, and L2 clinical and laboratory 170 strains. Two different clinical isolates were included in the non-9 assays against serovars 171 D, E, and J. In each assay, we included Polymyxin B as an active control and Penicillin 172 G as a minimally active control. Both of these control compounds behaved as expected 173 in all assays. 174 1-OG was 100% active for concentrations greater than or equal to 3.13mM and 175 then activity rapidly dropped below 50% inhibition (figure 1). The MCC for 1-OG was 176 statistically the same between clinical and prototype strains of serovars J and D 177 (3.13mM). However, at concentrations below 3.13mM, there was a statistically 178 significant difference between clinical and prototype activity for serovar J, with the 179 prototype strain being more sensitive to the lipid than the clinical strain (figure 1). 180 The G10 and SMAP-29 peptides showed more of a classical dose response curve; 183 activity was high for the higher test concentrations and then gradually fell off as the 184 dilutions decreased in concentration (figures 2-5). G10 and SMAP-29 activity was 185 similar against serovars D and E, but G10 was slightly more active. There were very few 186 differences when comparing sensitivities of clinical and prototype strains to both 187 peptides. 188
A C C E P T E D
Surgilube was very active (>75% inhibition) against serovars D and J at 189 concentrations ≥ 3.13% after a 120 minute exposure. The only differences between 190 clinical and prototype isolates of the same serovar were seen with serovar J after 191 exposure to 1.56%, 0.78%, and 0.39% surgilube, when the prototype isolate was 192 statistically significantly more sensitive to treatment (figure 6). 193
However, we observed marked differences between the clinical and prototype 194 isolates of the same serovar in some but not all serovars when tested against another 195 surfactant, non-9. For serovars D and J, the differences between clinical and prototype 196 strains were large, highly significant, and present over a large range of concentrations, 197 with the clinical strain showing much more resistance to the non-9 treatment (figures 7, 198 8). For example, when exposed to 0.25% non-9, the serovar D laboratory prototype 199 isolate (designation 9379) was inhibited by 16.8% (SD 5.9) when exposed to the same 207 concentration of non-9. The clinical isolates were not always less sensitive to non-9 than 208 the laboratory strains. Prototype F was found to be statistically significantly more 209 resistant to the non-9 treatment than a clinical F strain at some concentrations, though the 210 difference was not as large as seen in serovars J and D (figure 9). The clinical and 211 laboratory prototype serovar L2 had no significant difference in sensitivity to non-9 (data 212 not shown). The clinical and laboratory prototype E strains, had minor differences in 213 susceptibility at some of the lower concentrations, but in general, the activity was the 214 same (data not shown). concentrations must thus be limited to those which will produce reliable data. In our 223 MCC pre-inoculation assay, the compound is not required to enter the host cells, which 224 makes it the ideal assay for testing compounds whose ultimate purpose will be to act on 225 chlamydial EBs before they infect host cells. This assay is versatile and can be employed 226 Using our MCC assay, we found major differences between C. trachomatis 229 laboratory prototype strains and recent clinical isolates of the same serovar in 230 susceptibility to non-9. We also found minor differences between prototype and clinical 231 strains after exposure to some concentrations of another surfactant (surgilube), to two 232 peptides, and to a lipid, although these differences were not as dramatic as with non-9. 233
The mode of action of a surfactant (like non-9) is on the lipid component of the outer 234 membrane. Our results with non-9 suggest that the outer surface of prototype strains may 235 be different from that of clinical isolates. The membrane components of prototype strains 236 could have been altered during passages in the laboratory, resulting in a change in 237 sensitivity to non-9. An alternative explanation is that the clinical isolates may have 238 altered membrane components in order to survive repeated exposure to non-9 in the 239 environment. The latter explanation may be more plausible because surgilube, another 240 surfactant, did not affect clinical and prototype isolates in the same way. Surgilube has 241 been used in the medical environment for a long time, but it is used as a sterile surgical 242 lubricant, not as a method of birth control. This hypothesis is strengthened by the results 243 shown promising activity could be tested against clinical isolates to fully characterize the 257 potency of the microbicide. 258
Testing of clinical isolates could potentially be used as an additional step between 259
in-vitro screening with prototype strains and human or animal trials. Additional studies 260
should be undertaken to determine whether clinical strains behave similarly when 261 exposed to other microbicides. In summary, while it is true that some major differences 262 were seen between some C. trachomatis clinical and prototype isolates' susceptibility to 263 non-9, major differences in susceptibility to other 9 423 against C. trachomatis serovar J laboratory prototype strain and clinical isolates 1178 and 424 9379 after 120 minutes of exposure. All assay details described in the legend to Figure 1 . 425 were used. There is no standard deviation data available for isolate #2 against 1% non-9 426 due to partial cytotoxicity in one of the experiments. 427 Figure 9 . The MCC pre-inoculation assay was used to compare the activity of non-9 429 against C. trachomatis serovar F laboratory prototype strain and clinical isolate 9397 430 after 120 minutes of exposure. All assay details described in the legend to Figure 1 . were 431 used. 432
